Literature DB >> 7093108

Bioavailability of dihydroergotamine in man.

P J Little, G L Jennings, H Skews, A Bobik.   

Abstract

1 The pharmacokinetics of dihydroergotamine (DHE) in plasma were examined in six normotensive subjects after single acute doses of dihydroergotamine, 10 micrograms/kg i.v. and 10, 20 and 30 mg orally. 2 The mean apparent half-time of elimination was 2.37 +/- 0.29 h and plasma clearance of dHE was 1002 +/- 169 ml/min. 3 Mean apparent absorption of DHE determined from the 10 mg dose was 26.6 +/- 10% and ranged from 8.9 to 60.3%. The oral bioavailability after the 10, 20 and 30 mg doses averaged 0.47 +/- 0.07%, 0.59 +/- 0.13% and 0.52 +/- 0.14% respectively. Inter-patient variability in bioavailability was 6-fold. 4 The results indicate that pre-systemic 'first-pass' extraction of DHE is the main determinant of its oral bioavailability. Oral doses of the drug up to 30 mg do not saturate this extraction process resulting in apparently linear kinetics for the drug.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7093108      PMCID: PMC1402019          DOI: 10.1111/j.1365-2125.1982.tb01866.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  [Prevention of postoperative venous thromboembolism by means of heparin and dihydroergotamine after hip joint replacement].

Authors:  V V Kakkar; P G Bentley; D Lawrence; H A de Haas; V P Ward
Journal:  MMW Munch Med Wochenschr       Date:  1979-09-07

2.  Involvement of the sodium-potassium pump in the mechanism of postjunctional supersensitivity of the vas deferens of the guinea pig.

Authors:  W T Gerthoffer; J S Fedan; D P Westfall; K Goto; W W Fleming
Journal:  J Pharmacol Exp Ther       Date:  1979-07       Impact factor: 4.030

3.  Enhancement of the bioavailability of propranolol and metoprolol by food.

Authors:  A Melander; K Danielson; B Scherstén; E Wåhlin
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

4.  Haemodynamic effects of dihydroergotamine in patients with postural hypotension.

Authors:  S Bevegård; J Castenfors; L E Lindblad
Journal:  Acta Med Scand       Date:  1974-12

5.  Comparative effects of dihydroergotamine and noradrenaline on resistance, exchange and capacitance functions in the peripheral circulation.

Authors:  S Mellander; I Nordenfelt
Journal:  Clin Sci       Date:  1970-08       Impact factor: 6.124

6.  Determination of norepinephrine apparent release rate and clearance in humans.

Authors:  M Esler; G Jackman; A Bobik; D Kelleher; G Jennings; P Leonard; H Skews; P Korner
Journal:  Life Sci       Date:  1979-10-22       Impact factor: 5.037

7.  9-10-dihydroergotamine: production of antibodies and radioimmunoassay.

Authors:  J Rosenthaler; H Munzer
Journal:  Experientia       Date:  1976-02-15

8.  Treatment of orthostatic hypotension with dihydroergotamine.

Authors:  G Jennings; M Esler; R Holmes
Journal:  Br Med J       Date:  1979-08-04

9.  Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man.

Authors:  W H Aellig; E Nüesch
Journal:  Int J Clin Pharmacol Biopharm       Date:  1977-03

10.  Pindolol pharmacokinetics in relation to time course of inhibition of exercise tachycardia.

Authors:  G L Jennings; A Bobik; E T Fagan; P I Korner
Journal:  Br J Clin Pharmacol       Date:  1979-03       Impact factor: 4.335

View more
  17 in total

1.  Bioavailability of dihydroergosine in healthy volunteers.

Authors:  P Cvelbar; J Culig; Z Kopitar; A Lenardic; J U Smerkolj; M Zorz
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jan-Mar       Impact factor: 2.441

2.  Investigation of the venoconstrictor effect of 8' hydroxydihydroergotamine, the main metabolite of dihydroergotamine, in man.

Authors:  W H Aellig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Pharmacological actions of the main metabolites of dihydroergotamine.

Authors:  E Müller-Schweinitzer
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 4.  Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine.

Authors:  Stephen D Silberstein; Shashidhar H Kori
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

5.  Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man.

Authors:  G Maurer; W Frick
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Relationship between the venoconstrictor activity of dihydroergotamine and its pharmacokinetics during acute and chronic oral dosing.

Authors:  H de Marées; D Welzel; A de Marées; U Klotz; K U Tiedjen; G Knaup
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 7.  Pharmacokinetic interactions of topiramate.

Authors:  Meir Bialer; Dennis R Doose; Bindu Murthy; Christopher Curtin; Shean-Sheng Wang; Roy E Twyman; Stefan Schwabe
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Interspecies similarities in the disposition of 3H-dihydroergotamine following subcutaneous administration in man and rabbits.

Authors:  F L Tse; J M Jaffe
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jan-Mar       Impact factor: 2.441

Review 9.  Intranasal medications for the treatment of migraine and cluster headache.

Authors:  Alan M Rapoport; Marcelo E Bigal; Stewart J Tepper; Fred D Sheftell
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

10.  Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers.

Authors:  J J Ibraheem; L Paalzow; P Tfelt-Hansen
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.